Under UK GAAP, firms had the option to capitalise or expense development expenditures; under IFRS, development expenditures must be capitalised. R&D projects often rely on intellectual property—licensed technologies, drug compounds, or in-process development rights acquired from third parties. One of the more nuanced areas involves tangible assets like test equipment, supplies, and pilot plants. The […]

